Meeting
2019 ASCO Annual Meeting
SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
Authors
Sandip Pravin Patel
University of California, San Diego, Moores Cancer Center, San Diego, CA
Sandip Pravin Patel , Megan Othus , Young Kwang Chae , Frank Giles , Jourdain Hayward , Christine McLeod , Helen X. Chen , Elad Sharon , Edward Mayerson , Christopher W. Ryan , Melissa Plets , Charles David Blanke , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02834013
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2658)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2658
Abstract #
TPS2658
Poster Bd #
295a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.
First Author: Young Kwang Chae
First Author: Young Kwang Chae
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer.
First Author: Alice Markussen
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
First Author: Marit Ahrens